|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"huang c f"
Showing items 81-105 of 886 (36 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-01-12T07:07:34Z |
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
|
Lin C.-C.; HSIN-AN HOU; Chou W.-C.; Kuo Y.-Y.; Wu S.-J.; Liu C.-Y.; Chen C.-Y.; Tseng M.-H.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Hsu S.-C.; Ko B.-S.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:33Z |
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
|
Lin C.-C.; HSIN-AN HOU; Chou W.-C.; Kuo Y.-Y.; Liu C.-Y.; Chen C.-Y.; Lai Y.-J.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Ko B.-S.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:32Z |
The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression
|
Kuo Y.-Y.; HSIN-AN HOU; Chen Y.-K.; Li L.-Y.; Chen P.-H.; Tseng M.-H.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Chou W.-C.; Liu C.-Y.; Tang J.-L.; Yao M.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:32Z |
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression
|
HSIN-AN HOU; Kuo Y.-Y.; Tang J.-L.; Chou W.-C.; Yao M.; Lai Y.-J.; Lin C.-C.; Chen C.-Y.; Liu C.-Y.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Huang S.-Y.; Ko B.-S.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:31Z |
Clinical and prognostic implications of roundabout 4 (Robo4) in adult patients with acute myeloid leukemia
|
Chen Y.-K.; HSIN-AN HOU; Tang J.-L.; Jhuang J.-Y.; Lai Y.-J.; Lee M.-C.; Kuo Y.-Y.; Chou W.-C.; Liu C.-Y.; Lin C.-W.; Chuang S.-S.; Chen C.-Y.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:28Z |
GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution
|
HSIN-AN HOU; Lin Y.-C.; Kuo Y.-Y.; Chou W.-C.; Lin C.-C.; Liu C.-Y.; Chen C.-Y.; Lin L.-I.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-07T06:05:52Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; CHIH-YUAN LEE; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 國立成功大學 |
2022 |
Data science and reinforcement learning for price forecasting and raw material procurement in petrochemical industry
|
Lee, C.-Y.;Chou, B.-J.;Huang, C.-F. |
| 國立成功大學 |
2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
|
Lo, C.-C.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Chuang, W.-L.;Lin, H.-C.;Kao, J.-H.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang, C.-F.;Tseng, K.-C.;Cheng, P.-N.;Hung, C.-H.;Lo, C.-C.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Chen, Chen C.-H.;Lee, P.-L.;Lin, C.-Y.;Kuo, H.-T.;Chen, Chen C.-T.;Yang, C.-C.;Huang, J.-F.;Tai, C.-M.;Hu, J.-T.;Lin, C.-L.;Su, W.-W.;Tsai, W.-L.;Huang, Y.-H.;Cheng, Cheng C.-Y.;Lin, C.-L.;Wang, C.-C.;Yang, S.-S.;Mo, L.-R.;Chen, G.-Y.;Chang, Chang C.-C.;Wang, S.-J.;Huang, C.-S.;Hsieh, T.-Y.;Lin, C.-W.;Lee, T.-H.;Chong, L.-W.;Huang, C.-W.;Chang, S.-N.;Tsai, M.-C.;Hsu, S.-J.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Lin, H.-C.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Chuang, W.-L.;Chen, Chen C.-Y.;Yu, M.-L. |
| 國立成功大學 |
2022 |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
|
Chen, Y.-C.;Chang, T.-S.;Chen, Chen C.-H.;Cheng, P.-N.;Lo, C.-C.;Mo, L.-R.;Chen, Chen C.-T.;Huang, C.-F.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L.;investigators, on behalf of TACR |
| 國立成功大學 |
2022 |
Sofosbuvir/Velpatasvir for Hepatitis�C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng, P.-N.;Mo, L.-R.;Chen, Chen C.-T.;Chen, Chen C.-Y.;Huang, C.-F.;Kuo, H.-T.;Lo, C.-C.;Tseng, K.-C.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Chou, K.-H.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Cheng, Cheng C.-Y.;Tsai, M.-C.;Liu, C.-J.;Dai, C.-Y.;Lin, H.-C.;Kao, J.-H.;Chuang, W.-L.;Yu, M.-L.;investigators, TACR |
| 臺大學術典藏 |
2021-12-22T03:53:44Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:39Z |
Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy
|
Lin S.-Y.; Tang S.-C.; Tsai L.-K.; Yeh S.-J.; Huang C.-F.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:33Z |
Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
|
Lin S.-Y.; Peng Y.-F.; Huang C.-F.; Kuo C.-H.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:31Z |
Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Ho L.-T.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-22T03:53:29Z |
Impact of different renal function equations on direct oral anticoagulant concentrations
|
Lin S.-Y.; Kuo C.-H.; Huang T.-M.; Peng Y.-F.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2021-12-02T05:41:25Z |
Primary hypogammaglobulinemia presenting with prostate abscess and Fusobacterium mortiferum bacteremia in a 28-year-old man
|
Lu C.-H.; WANG-DA LIU; Huang C.-F.; Liao C.-H.; Lan T.-Y.; Kang C.-M.; Lin C.-C.; Yang Y.-H.; Hung C.-C. |
| 臺大學術典藏 |
2021-11-26T05:56:25Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; LI-KAI TSAI; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-11-26T05:56:20Z |
Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy
|
Lin S.-Y.; Tang S.-C.; LI-KAI TSAI; Yeh S.-J.; Huang C.-F.; Jeng J.-S. |
| 臺大學術典藏 |
2021-10-18T06:51:39Z |
Ultrastructural changes of posterior lingual glands after hypoglossal denervation in hamsters
|
Cheng S.J.; Huang C.F.; Chen Y.C.; Lee J.J.; Chang H.H.; HSIN-MING CHEN; Chiang M.L.; Kuo M.Y.; Kok S.-H.; Tseng C.-Y. |
| 臺大學術典藏 |
2021-09-23T03:35:36Z |
Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
|
Lin S.-Y.; Peng Y.-F.; Huang C.-F.; Kuo C.-H.; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
|
Yu M.-L.; Liu C.-H.; Huang C.-F.; Tseng T.-C.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.-H.H.; Chuang W.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:49Z |
Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype
|
Huang C.-F.; Yu M.-L.; JIA-HORNG KAO; Tseng T.-C.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.H.H.; Chuang W.-L.; Liu C.-H. |
| 臺大學術典藏 |
2021-09-04T06:11:44Z |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO |
Showing items 81-105 of 886 (36 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
